henhaobio
Sign in

Nature CommunicationsSynthetic BiologyPeer-reviewed journal article

AI-driven discovery and engineering of human endogenous nanocage proteins for mRNA delivery

Dongmin XuniD, Lanqing LiiD, Jie ZouiD, Yi LiuiD, Ziyue YangiD, Qianyi Liang, Ke LiiD, Zhu ZhuiD, Jicong ZhangiD, Lijun LangiD, Kun Liu, Xinyu Wang, Meilin TianiD, Guangyong CheniD, Bolin AniD, Pheng‐Ann HengiD, Chao ZhongiD

PDFDOIPreprint

Abstract

Safe and effective gene delivery remains a central challenge for therapeutic applications. While non-viral and viral vectors have enabled substantial progress, their reliance on non-human components often triggers immune responses, limiting their use in chronic treatments. Here, we developed DeepDelivery, an artificial intelligence-driven platform to repurpose human proteins for mRNA delivery. An unbiased screening of the human proteome nominated 512 candidates, with experimental validation confirming that 80% of top-ranked hits form mRNA-encapsulating particles and mediate efficient functional delivery in human cells without provoking detectable inflammation. Notably, multiple tripartite motif (TRIM) family proteins, typically linked to antiviral responses, exhibited strong assembly and delivery activity. Quantitative analysis and interpretation of the model revealed structural domains that govern nanocage formation, enabling domain-guided engineering of TRIM25 variants with enhanced function. Our work establishes a generalizable framework for discovering human-derived delivery vehicles and provides a path toward programmable, non-immunogenic mRNA therapeutics.

Citations
0
FWCI
0.00
Field percentile
6th percentile

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISXu '23Zickler '23Zheng '26Zheng '22Ma '26Knappenberg '26
62% semantic matchBiochemistry
Y. Xu, S. Ma, H. Cui+7 more·bioRxiv·Jun 1, 2023